AERWINS Technologies Inc. · OTC:AWIN

AERWINS Technologies — Pono Capital — Debt Investor Presentation (May 2022)

33 slides from AERWINS Technologies's debt investor presentation, May 4, 2022

  1. Slide 1: $50 Million Senior Secured Convertible Notes Investor Presentation

    Slide 1: $50 Million Senior Secured Convertible Notes Investor Presentation

    AS ; } Benuvia’ WIA $50 MILLION SENIOR SECURED CONVERTIBLE NOTES INVESTOR PRESENTATION May 2022

  2. Slide 2: Disclaimers: Forward Looking Statements

    Slide 2: Disclaimers: Forward Looking Statements

    DISCLAIMERS LC Benuvia FORWARD LOOKING STATEMENTS CERTAIN INFORMATION SET FORTH IN THIS PRESENTATION, TOGETHER WITH ANY SUPPLEMENTS AND ANY OTHER INFORMATION THAT MAY BE FURNISHED TO PROSPECTIVE INVESTORS BY BENUVIA, INC. IN CONNECTION THEREWITH, CONTAINS “FORWARD-LOOKING STATEMENTS” AND “FORWARD-LO

  3. Slide 3: Disclaimers: Summary Risk Factors

    Slide 3: Disclaimers: Summary Risk Factors

    DISCLAIMERS LC Benuvia SUMMARY RISK FACTORS RISK FACTORS THAT COULD CAUSE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENT TO DIFFER MATERIALLY FROM THOSE INDICATED IN THE FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED. TO THE FOLLOWING: (I) THE RISK THAT THE COMPANY WILL BE UNABLE TO RAISE THE A

  4. Slide 4: Disclaimers: Other Information

    Slide 4: Disclaimers: Other Information

    DISCLAIMERS LC Benuvia OTHER INFORMATION THIS PRESENTATION DOES NOT CONTAIN ALL OF THE INFORMATION THAT WOULD NORMALLY APPEAR IN A PROSPECTUS UNDER APPLICABLE UNITED STATES SECURITIES LAWS. NEITHER THE DELIVERY OF THIS PRESENTATION, AT ANY TIME, NOR ANY SALE MADE PURSUANT TO OR IN CONNECTION WITH TH

  5. Slide 5: Executive Summary

    Slide 5: Executive Summary

    ~~ Po EXECUTIVE SUMMARY IG senuvia Company Overview o Benuvia, Inc. (“Benuvia" or the “Company” is a leading drug developer and manufacturer of active pharmaceutical ingredients (“APIs”) focused on cannabinoids, with a growing portfolio of drug products and intellectual property o The Company has on

  6. Slide 6: Summary of Proposed Terms

    Slide 6: Summary of Proposed Terms

    a> _ SUMMARY OF PROPOSED TERMS | ~Benuvia Issuer: Benuvia, Inc. (the “Company”). Issue: $50.0 million Senior Secured Convertible Notes (the “Notes”). Term: 4 Years. Optional Prepayment: NC2. To refinancing existing indebtedness, working capital, general corporate purposes, and pay transaction fees a

  7. Slide 7: Transaction Summary

    Slide 7: Transaction Summary

    TRANSACTION SUMMARY ($ in millions) Sources of Funds a New Sr. Sec. Convertible Notes 50.0 Repay Existing Debt 38.1 Non-Redeeming Holders (SPAC)!") 25.0 General Corporate Purposes 32.9 $50M Undrawn Equity Line of Credit!?) = Fees and Expenses 4.0 Total Sources of Funds $ 75.0 Total Uses of Funds Ss

  8. Slide 8: Investment Highlights

    Slide 8: Investment Highlights

    ~~ oo INVESTMENT HIGHLIGHTS IG senuvia SYNDROS®: The Only Cll Tetrahydrocannabinol (THC) Oral Liquid Solution Approved by the FDA ° approved for adults as a second-line treatment of “CINV” and for anorexia associated with weight loss in patients with Revenue Generating Captive Cannabinoid Manufactur

  9. Slide 9: Board of Directors and Management

    Slide 9: Board of Directors and Management

    BOARD OF DIRECTORS AND MANAGEMENT* Shannon Soqui Executive Chairman 20 Year Investment Banking Veteran with DLJ, Credit Suisse and UBS; Former Securities Lawyer, and CPA with KPMG Dr. Sud Agarwal Board-Certified Anesthesiologist and Drug Developer. CEO of Cannvalate, CMO of Incannex Scott Aladeen Ch

  10. Slide 10: Company Overview

    Slide 10: Company Overview

    Kas . : (Cpenuvia Company Overview

  11. Slide 11: Corporate Overview

    Slide 11: Corporate Overview

    a> _ CORPORATE OVERVIEW ks Benuvia Leading Drug Developer and Manufacturer of Pharmaceutical Cannabinoids and Psychedelics Owner of FDA Approved SYNDROS® (Dronabinol Oral Liquid Solution; THC) One of The Largest Synthetic Cannabinoid Manufacturing Facilities in the US” Active Pharmaceutical Ingredie

  12. Slide 12: Pharmaceutical Cannabinoid Manufacturing

    Slide 12: Pharmaceutical Cannabinoid Manufacturing

    PHARMACEUTICAL CANNABINOID MANUFACTURING ~~ 7 c Benuvia Active Pharmaceutical Ingredient Manufacturing Facility” One of the Largest Synthetic Cannabinoid and Psychedelics Manufacturing Facilities in the US” FDA-Registered Site for Manufacturing, Packaging and Testing of Active Pharmaceutical Ingredi

  13. Slide 13: Pharmaceutical Cannabinoid Manufacturing (Continued)

    Slide 13: Pharmaceutical Cannabinoid Manufacturing (Continued)

    a> _ PHARMACEUTICAL CANNABINOID MANUFACTURING (CONTINUED) IG senuvia Special formulation equipment for efficient and flexible manufacturing Optimally suited facility for small-scale API manufacturing Fully equipped laboratories with broad analytical capabilities Ka ~ —_ - Benuvia Purpose fit set-up

  14. Slide 14: Contract Manufacturing Overview

    Slide 14: Contract Manufacturing Overview

    CONTRACT MANUFACTURING OVERVIEW S a IG senuvia Contract Development and Manufacturing (CDMO) Primary Capabilities (Formulated Solutions) Contract Development Contract Manufacturing Primary Formulation Compounds THC Existing Customer pa Radius’ Radius Health NASDAQ: RDUS. Development and Supply Agree

  15. Slide 15: SYNDROS Overview

    Slide 15: SYNDROS Overview

    SYNDROS® OVERVIEW ~~ 7 ( e Benuvia SYNDROS® (Dronabinol) is an FDA Approved Cll Tetrahydrocannabinol (THC) Oral Liquid Solution @SYNDROS’ (dronabinol) oral solution, Cll Only FDA Approved THC Oral Liquid Solution Bx 70082:3350 Launched In 2017 : eed ; 5 Smgimt FDA-Approved for the Treatment “Siynple

  16. Slide 16: History of SYNDROS

    Slide 16: History of SYNDROS

    ~~ oo HISTORY OF SYNDROS IG senuvia 2015 2017 2019 Present o Insys Therapeutics Inc. o Full market authorization o Insys declares o Benuvia plans to fully (“Insys”) applies for FDA for SYNDROS® received bankruptcy and divests market SYNDROS® approval for SYNDROS® SYNDROS® (drabinol oral solution) 20

  17. Slide 17: SYNDROS Commercialization Plan

    Slide 17: SYNDROS Commercialization Plan

    SYNDROS® COMMERCIALIZATION PLAN Ka S Commercial Growth Strategy Begins With Market Re-introduction of SYNDROS® 5-10 New Patients Monthly Current Status No Patient Marketing No HCP Marketing No Dedicated Sales Teams No Vendor Contracts @SYNDROS (dronabinol) oral solution, Cll Q2-Q4 2022 Marketing Pat

  18. Slide 18: Drug Development

    Slide 18: Drug Development

    Kas 7 (Cpenuvia Drug Development

  19. Slide 19: Drug Development Platform

    Slide 19: Drug Development Platform

    a> _ DRUG DEVELOPMENT PLATFORM IG senuvia We Leverage a Platform of Capabilities to Expedite our Drug Development Timeline CLINICAL DRUG DEVELOPMENT PIPELINE Pancreatic FDA APPROVED DRUG @SYNDROS’ (dronabinol) oral solution, Cll CAPABILITIES PLATFORM Registered yA In-House API Quality and Safety FDA

  20. Slide 20: Drug Development Timeline

    Slide 20: Drug Development Timeline

    > _ DRUG DEVELOPMENT TIMELINE IG senuvia Timeline & Cost to New Drug Approval (NDA) Significantly Compressed Standard Drug Development Process and Timing Drug Discovery/ Pre-Clinical Studies Phase | Phase II Phase III Study Study Study 6 to 8+ Years 1 to 2 Years 1 to 2 Years 2 to 3 Years $5M+ $2-3M

  21. Slide 21: Clinical Drug Development Pipeline: Progress to Date

    Slide 21: Clinical Drug Development Pipeline: Progress to Date

    a> _ CLINICAL DRUG DEVELOPMENT PIPELINE: PROGRESS TO DATE | ~Benuvia cation [nicer | nose | rt ed ee es CINV and Anorexia in AIDS Patient SYNDRO owed oa ED Nanproved a FDA Approved Liquid Dronabinol (THC) Pune] BEN-166S Alzheimer’s Disease Agitation Cost to No FDA Le p ‘ i Complete NDA’ Approved s12

  22. Slide 22: Portfolio of Patents Issued and Pending

    Slide 22: Portfolio of Patents Issued and Pending

    PORTFOLIO OF PATENTS ISSUED AND PENDING S a IG senuvia Patents No. US8222292, US9345771, US10265293, US11253472 Liquid Dronabinol Formulations Patent No. 9,370,518, 9,662,334, 10,111,833 Sildenafil Sublingual Spray Patent No. 9,839,611, 9,918,981 Sublingual Buprenorphine + Naloxone Spray Patent No.

  23. Slide 23: Equity Comparables and Selected Precedent Transactions

    Slide 23: Equity Comparables and Selected Precedent Transactions

    (Cpenuvia Equity Comparables and Selected Precedent Transactions

  24. Slide 24: Benuvia Positioning vs. Comparable Drug Developers

    Slide 24: Benuvia Positioning vs. Comparable Drug Developers

    a> _ BENUVIA POSITIONING VS. COMPARABLE DRUG DEVELOPERS | ~Benuvia ($ in millions) Comparable Drug Development Companies Include the Following: i /\ventyx f Vv, ee me Q ~ GEdcewise — YIVEREYE = @ ct Research CASSAVA aso REQ d Inflammatory ets ; Psychiatric and i ‘ Oncology and Musculoskeletal Diseas

  25. Slide 25: Benuvia Positioning vs. Cannabinoid/Psychedelic Companies

    Slide 25: Benuvia Positioning vs. Cannabinoid/Psychedelic Companies

    BENUVIA POSITIONING VS. CANNABINOID/PSYCHEDELIC COMPANIES ($ in millions) Ka ~~ 7 ks Benuvia Comparable Cannabinoids/Psychedelics Companies Include the Following: ° Incannex® &B MindMed ) COMPASS O atal @cu Research x ala LIFE SCIENCES, Phatmace vical Pharmaceutical Pharmaceutical Pharmaceutical Pha

  26. Slide 26: Recent M&A Transactions in the Industry

    Slide 26: Recent M&A Transactions in the Industry

    RECENT M&A TRANSACTIONS IN THE INDUSTRY ~~ 7 c Benuvia G- @ Pharmaceuticals Jazz Pharmaceuticals’ GW Pharma was Acquired by Jazz Pharmaceuticals in 2021 for $7.2B Source: Jor Phoma Company Overview Name: GW Pharmaceuticals Location: London, UK Exchange: NASDAQ 2020 Revenue: $500M Acquisition Value:

  27. Slide 27: Appendix

    Slide 27: Appendix

    Kas ._. . ICpenuvia Appendix

  28. Slide 28: Indication Overview: Alzheimer's Disease Agitation

    Slide 28: Indication Overview: Alzheimer's Disease Agitation

    a> _ INDICATION OVERVIEW: ALZHEIMER’S DISEASE AGITATION Ks Benuvia ; : Gap Analysis to New Drug Approval Alzheimer’s Disease H H i: Pre-IND Open IND Phase 1 Phase 2 Phase 3 NDA Agitation (Agit-AD) P Completed Under Clinical trial Clinical trial__—-Targeting 2021 Submission Eyempted) 2H 2022 targetin

  29. Slide 29: Indication Overview: Anorexia in Cancer

    Slide 29: Indication Overview: Anorexia in Cancer

    a> _ INDICATION OVERVIEW: ANOREXIA IN CANCER | ~Benuvia Gap Analysis to New Drug Approval Anorexia in Cancer Pre-IND Open IND Phase 1 Phase 2 Phase 3 NDA 6months prep, 12months _ Targeting 6 months trial prep, 2H 2024 12 months trial Completed Completed —_ Exempted Existing Data fo Support Dronabino

  30. Slide 30: Indication Overview: Pancreatic Cancer

    Slide 30: Indication Overview: Pancreatic Cancer

    Ka > _ INDICATION OVERVIEW: PANCREATIC CANCER | ~Benuvia Pancreatic Cancer 355,317 New Pancreatic Cancer Cases Estimated to Occur Globally by 20402 $2 Billion Global Pancreatic Cancer Estimated Market Size in 2020! $4.2 Billion Global Pancreatic Cancer Estimated Market Size by 2025! Orphan Drug Desi

  31. Slide 31: Sildenafil Product Overview

    Slide 31: Sildenafil Product Overview

    a> _ SILDENAFIL PRODUCT OVERVIEW ks Benuvia US PATENTS: Sildenafil is Used to Treat Erectile Dysfunction (ED) os in Men and Pulmonary Arterial Hypertension OlUTION Benuvia Owns Several Patents for Sildenafil Sublingual Spray Formulations Market Opportunity Applications Product Benefits Market Size M

  32. Slide 32: Drug Development: Drug Master Files

    Slide 32: Drug Development: Drug Master Files

    ~~ oo DRUG DEVELOPMENT: DRUG MASTER FILES IG senuvia The Following Drug Master Files (DMFs) Provide a Foundation for Product Extensions: THC CBD DRONABINOL USP CANNABIDIOL H,C CH, CH3 (DME 19207) (DMF 32552 - Generation 2) 32

  33. Slide 33: <——_> EF

    Slide 33: <——_> EF

    <——_> EF

Source: SEC EDGAR · 8-K filed May 4, 2022

More decks from AERWINS Technologies Inc.

All 3 AERWINS Technologies decks